
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
View the Pharmaceutical Executive October 2025 issue in an interactive format.
Click
about 1 year ago
Price Checksabout 1 year ago
Bob Mauch: Strengthening the Chainabout 1 year ago
A Brave New World: Implications of the IRA on Brand Strategyabout 1 year ago
From ‘Pilotitis’ to Productivity: Reimagining AI’s Role in R&Dabout 1 year ago
Elevate Earned Media Through Continuing Educationabout 1 year ago
Navigating the Complexities of a Global Pharma Expansion





